Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 37, 2012, Pages 15001-15005

  Grosset, Jacques ^a,b   Almeida, Deepak ^a   Converse, Paul J ^a   Tyagi, Sandeep ^a   Li, Si Yang ^a   Ammerman, Nicole C ^a,b   Pym, Alexander S ^b   Wallengren, Kristina ^b   Hafner, Richard ^c   Lalloo, Umesh ^b   Swindells, Susan ^d   Bishai, William R ^a,b,e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Chemotherapy; Mycobacterium

Indexed keywords

ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TREATMENT WITHDRAWAL; TUBERCULOSIS;

ANALYSIS OF VARIANCE; ANIMALS; ANTITUBERCULAR AGENTS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; DRUG THERAPY, COMBINATION; EARLY MEDICAL INTERVENTION; ISONIAZID; MICE; MODELS, BIOLOGICAL; PYRAZINAMIDE; TREATMENT OUTCOME; TUBERCULOSIS;

MURINAE; MYCOBACTERIUM;

EID: 84866281146     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1203636109     Document Type: Article

References (22)

1. World Health Organization (2011) Global tuberculosis control: WHO report 2011 (WHO Press, Geneva).
2. World Health Organization (2009) Treatment of tuberculosis: Guidelines. (WHO Press, Geneva), 4th Ed.
3. Canetti G (1962) The eradication of tuberculosis: Theoretical problems and practical solutions. Tubercle 43:301-321.
4. Jindani A, Aber VR, Edwards EA, Mitchison DA (1980) The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 121:939-949.
5. Donald PR, Diacon AH (2008) The early bactericidal activity of anti-tuberculosis drugs: a literature review. Tuberculosis (Edinb) 88(Suppl 1):S75-S83.
6. Jindani A, Doré CJ, Mitchison DA (2003) Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 167:1348-1354.
7. David HL (1970) Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol 20:810-814.
8. Almeida D, et al. (2009) Paradoxical effect of isoniazid on the activity of rifampinpyrazinamide combination in a mouse model of tuberculosis. Antimicrob Agents Chemother 53:4178-4184.
9. Pletz MW, et al. (2004) Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 48:780-782.
10. Johnson JL, et al. (2006) Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 10:605-612.
11. Nuermberger EL, et al. (2004) Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 169:421-426.
12. Zhang Y, Mitchison D (2003) The curious characteristics of pyrazinamide: A review. Int J Tuberc Lung Dis 7:6-21.
13. Shi W, et al. (2011) Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 333:1630-1632.
14. Diacon AH, et al. (2010) Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother 54:3402-3407.
15. Diacon AH, et al. (2011) Early bactericidal activity of delamanid (OPC-67683) in smearpositive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 15:949-954.
16. Diacon AH, et al. (2012) 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet, 10.1016/S0140-6736(12)61080-0.
17. Loudon RG, Spohn SK (1969) Cough frequency and infectivity in patients with pulmonary tuberculosis. Am Rev Respir Dis 99:109-111.
18. Nuermberger E, et al. (2006) Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 50:2621-2625.
19. Zhang M, et al. (2011) Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. Am J Respir Crit Care Med 183:1254-1261.
20. Dhillon J, Dickinson JM, Sole K, Mitchison DA (1996) Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. Antimicrob Agents Chemother 40:552-555.
21. Dickinson J, Guy A, Mitchison DA (1992) Bioavailability of rifampin in experimental murine tuberculosis. Antimicrob Agents Chemother 36:2066-2067.
22. Grosset J, Truffot-Pernot C, Lacroix C, Ji B (1992) Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 36:548-551.